|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This confirms previous immunohistological data indicating that non-Hodgkin's lymphomas which express the Ki-1 antigen may be of either T-cell or B-cell origin.
|
3040565 |
1987 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In order to contribute to the characterization of the molecular mechanisms of this disease, cDNAs coding for the HD characteristic antigen CD30 were cloned from expression libraries of the human HUT-102 cell line using the monoclonal antibodies Ki-1 and Ber-H2.
|
1310894 |
1992 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The neoplastic cells in Hodgkin's disease are often CD30-positive, as are some of the transformed lymphocytes in infectious mononucleosis.
|
1323222 |
1992 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Distribution and phenotype of Epstein-Barr virus (EBV)-harboring cells were determined in Hodgkin's disease (HD) biopsies by in situ hybridization with [35S]-labeled RNA probes specific for the small EBV-encoded nuclear RNAs, EBER1 and EBER2, in some instances preceded by immunohistology for CD20, CD30, CD45RO, and CD68 antigens, the T-cell receptor beta-chain, and latent membrane antigen (LMP) of EBV.
|
1320954 |
1992 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ki-1-positive large cell anaplastic lymphoma (Ki-1 LCAL) is recognized as a clinicopathologic syndrome with fever, peripheral lymphadenopathy and cutaneous nodules; the neoplastic cells express Hodgkin's disease-associated antigen, Ki-1 (CD30).
|
1337292 |
1992 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of this study indicate that Epstein-Barr virus genomes might be identified in more than 50% of the evaluated high grade non-Hodgkin's lymphomas; this association occurred significantly more often in the small noncleaved cell lymphomas resembling endemic Burkitt's lymphoma (60%) and with ALC CD30/BerH2+ lymphomas (77.8%).
|
8383422 |
1993 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD30 is a surface marker for neoplastic cells of Hodgkin's lymphoma and shows sequence homology to members of the tumor necrosis factor (TNF) receptor superfamily.
|
8391931 |
1993 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tissue specimens from 26 cases of Hodgkin's disease (HD) and six HD-derived cell lines were analysed for tumour necrosis factor (TNF), lymphotoxin (LT), and interleukin (IL)-6 RNA transcripts by in situ hybridization, in some cases subsequent to immunohistology for CD30 antigen.
|
8217820 |
1993 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative approach to the immunohistochemical analysis of p53 antioncogene and CD30 antigen in Hodgkin' disease.
|
8218985 |
1993 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ten months following the diagnosis of Hodgkin's disease (HD), a 46-year-old woman presented cutaneous and leukemic involvement by CD30+ anaplastic large cells, from which a continuously growing, exogenous growth factor-independent T cell line was established.
|
8035614 |
1994 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, CD40L induced a 40% to 60% reduction of the expression of the HD-associated CD30 antigen, another member of the TNF receptor superfamily.
|
7522624 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abnormalities in Hodgkin's disease were restricted to CD30-positive Reed-Sternberg cells.
|
7520272 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these data suggest that the CD30L-CD30 interaction has potent biological activity and might play a critical role in the immune response and pathogenesis of HD and some NHL, in particular Burkitt lymphomas.
|
7528856 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas.
|
7507733 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Morris et al., Science (Washington DC), 263: 1281-1284, 1994] is associated with Ki-1 (CD30)-positive anaplastic large cell lymphomas (ALCL); a group of morphologically and immunophenotypically heterogenous high grade large cell lymphomas (LCL), which share many characteristics with Hodgkin's disease (HD), including the presence of variable numbers of Reed-Sternberg-like cells and the expression of CD30 antigen.
|
8187071 |
1994 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We were unable to find polymerase chain reaction evidence for the t(2;5) in any of the cases of HD, a result significantly different from our previous study of CD30+ non-Hodgkin's lymphomas (P < .02) including ALCL (P < .04), using identical methods.
|
7742546 |
1995 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, positive FAS/APO-1 immunostaining was observed only in 22 out of 41 (53%) CD30 negative non-Hodgkin's lymphomas.
|
8522287 |
1995 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cells expressed the HD-associated surface antigens CD30 and CD15 as well as the transferrin receptor (CD71).
|
8605360 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diagnostic immunophenotypic differences were found between CD30+ DLCL and HD.
|
8639911 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hodgkin's disease (HD) represents a phenotypically and genotypically heterogeneous lymphoma of CD30-positive tumour cells.
|
8946602 |
1996 |
|
Hodgkin Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the role of the t(2;5) translocation in these diseases, we developed a DNA-based polymerase chain reaction (PCR)/Southern blot assay to detect this translocation at the genomic level in lymphomatoid papulosis (14 cases), primary cutaneous CD30+ large cell lymphoma of T-lineage (10 cases) and Hodgkin's disease (13 cases).
|
8781433 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To this end, we assessed the relative frequency of mitotic phases and nuclear damage (detected by in situ end-labeling of DNA strand breaks) in CD30+ large cells of nodular sclerosis and mixed cellularity HD.
|
8724538 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
EBV-positive samples from CD30-positive ALC lymphomas carried type 1 EBV (two of two specimens tested), whereas both EBV subtypes were observed in SNCC lymphomas and HD samples.
|
8617454 |
1996 |
|
Hodgkin Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The CD30 antigen has been characterized as a marker for cultured and primary Hodgkin and Reed-Sternberg cells, and was found to be overexpressed in Hodgkin disease and a subgroup of non-Hodgkin lymphomas including large cell anaplastic lymphomas and Burkitt lymphomas.
|
8833395 |
1996 |
|
Hodgkin Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure of HD cells to CD30 ligand induces release of interleukin-6 (IL-6) that can be duplicated by cross-linking HD-cells to an agonistic anti-CD30 specific monoclonal antibody (alphaCD30), but not by cross-linking to an isotype-identical irrelevant monoclonal antibody.
|
8630409 |
1996 |